CryoPort Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
6,382.40
19,565.40
7,026.90
10,403.00
7,899.00
9,555.60
Depreciation, Depletion & Amortization
394.00
311.60
197.90
301.30
664.80
857.90
Other Funds
762.30
15,090.90
2,269.10
6,623.20
3,751.60
6,832
Funds from Operations
5,226.20
4,162.90
4,559.80
3,478.50
3,482.60
1,865.70
Changes in Working Capital
441.00
217.70
432.10
264.70
100.50
1,486.70
Net Operating Cash Flow
4,785.10
4,380.70
4,127.70
3,743.20
3,583.10
3,352.40
Capital Expenditures
178.70
138.90
70.10
662.70
1,800.60
Net Investing Cash Flow
178.70
138.90
70.10
662.70
1,800.60
Issuance/Reduction of Debt, Net
909.40
3,999.10
533.30
325.40
656.20
Net Financing Cash Flow
909.40
4,326.00
5,233.40
6,137.90
15,901.40
Net Change in Cash
4,054.40
193.50
1,035.60
1,732.00
10,517.70
Free Cash Flow
4,941.30
4,519.50
4,197.80
4,400.90
5,298.10
Change in Capital Stock
-
326.90
4,700.20
6,463.30
16,557.60

About CryoPort

View Profile
Address
17305 Daimler Street
Irvine California 92614
United States
Employees -
Website http://www.cryoport.com
Updated 07/08/2019
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures.